Correspondence 0001493152-24-014542 from Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics, Inc.
Date: April 15, 2024 · CIK: 0001855485 · Accession: 0001493152-24-014542
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276741
Letter
Re:
April 15, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
Attention: Tyler Howes
Calidi Biotherapeutics, Inc.
Registration Statement on Form S-1 (Registration No. 333-276741)
Concurrence in Acceleration Request
Ladies and Gentlemen:
Ladenburg Thalmann & Co., Inc. (“Ladenburg”), solely acting as placement agent on a reasonable best efforts basis in an offering pursuant to the registration statement on Form S-1 (333-276741) (the “Registration Statement”), hereby concurs in the request by Calidi Biotherapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 4:30 P.M. (Eastern Time), or as soon as practicable thereafter, on April 15, 2024, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.
Very
truly yours,
LADENBURG
THALMANN & CO. INC.
Show Raw Text
CORRESP
1
filename1.htm
April
15, 2024
VIA
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
DC 20549
Attention:
Tyler Howes
Re:
Calidi
Biotherapeutics, Inc.
Registration
Statement on Form S-1 (Registration No. 333-276741)
Concurrence
in Acceleration Request
Ladies
and Gentlemen:
Ladenburg
Thalmann & Co., Inc. (“Ladenburg”), solely acting as placement agent on a reasonable best efforts basis in an offering
pursuant to the registration statement on Form S-1 (333-276741) (the “Registration Statement”), hereby concurs in the request
by Calidi Biotherapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 4:30 P.M. (Eastern
Time), or as soon as practicable thereafter, on April 15, 2024, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that
it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.
Very
truly yours,
LADENBURG
THALMANN & CO. INC.
By:
/s/
Nicholas Stergis
Name:
Nicholas
Stergis
Title:
Managing
Director
cc:
Andrew
Jackson, Calidi Biotherapeutics, Inc.
Richard
A. Friedman, Sheppard, Mullin, Richter & Hampton LLP
Stephen
A. Cohen, Sheppard, Mullin, Richter & Hampton LLP
Daniel
Eng, Lewis Brisbois Bisgaard & Smith LLP